GeoVax and ViaMune to Collaborate on Cancer Immunotherapy Program

ATLANTA, GA (Marketwired Nov 7, 2016) GeoVax Labs, Inc. (OTCQB: GOVX) announced today its collaboration with ViaMune, Inc. for the co-development of each company s cancer immunotherapy programs. Both companies products target an abnormal form of the autologous cell surface-associated protein, Mucin 1 (MUC1), which is over-expressed in the majority of known tumor types. Due to overexpression and/or aberrant glycosylation of MUC1, this tumor-associated antigen (TAA) is often recognized as abnormal by patients immune system but is not sufficiently immunogenic
http://bit.ly/2fU8E3x